SCHEMBL4152201

SCHEMBL4152201

O=C(Nc1cnc2ccccc2c1)c1ccnc2[nH]c(-c3ccc(F)cc3)nc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.53
KDR P35968 10/20 0.50
NPC1 O15118 4/20 0.50
RAB9A P51151 4/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
ALDH1A1 P00352 1/20 0.49
FLT1 P17948 1/20 0.48
TMPRSS4 Q9NRS4 1/20 0.47
MAPT P10636 1/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
KDM4E B2RXH2 1/20 0.46
MITF O75030 1/20 0.46
XBP1 P17861 1/20 0.46
PAX8 Q06710 1/20 0.46
KLF5 Q13887 1/20 0.46
HDAC4 P56524 1/20 0.45
CNR1 P21554 1/20 0.45
CNR2 P34972 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4156506 0.89 GSK3B (0.52) GSK3BKDRNPC1RAB9ASMN1; SMN2
SCHEMBL4161624 0.88 GSK3B (0.52) GSK3BNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL4152144 0.86 GSK3B (0.60) GSK3BNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL4156450 0.83 GSK3B (0.74) GSK3BALDH1A1KDM4E
SCHEMBL4152806 0.82 GSK3B (0.57) GSK3BSMN1; SMN2ALDH1A1MAPTKDM4E
SCHEMBL4145800 0.81 GSK3B (0.52) GSK3BKDR
SCHEMBL4161516 0.81 GSK3B (0.54) GSK3BNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL4152183 0.81 GSK3B (0.56) GSK3B
SCHEMBL4152791 0.81 GSK3B (0.73) GSK3BNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL4152842 0.80 GSK3B (0.52) GSK3BALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 GSK3B 1/4885KDR 1697/4885NPC1 2497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.